Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Rhea-AI Summary

Dermata Therapeutics (NASDAQ: DRMA) entered into definitive agreements for a private placement priced at-the-market under Nasdaq rules, issuing 2,293,608 shares of common stock (or pre-funded warrants) plus series E and short-term series F warrants to purchase up to 4,587,216 additional shares at $1.46 per share and accompanying warrants.

The placement is expected to close on or about August 18, 2026, generating approximately $3.4 million in gross proceeds, with up to about $6.7 million in potential additional gross proceeds if all warrants are exercised for cash. Company insiders, including the CEO and CFO, are participating at a $1.47 purchase and exercise price. According to Dermata Therapeutics, net proceeds will support general corporate purposes, including consumer research, launch activities for its planned August 25, 2026 direct-to-consumer skin renewal product, licensing, potential acquisitions, and working capital. The securities are being issued in a private offering under Section 4(a)(2) and/or Regulation D, with agreed resale registration rights.

Positive

• Gross proceeds of approximately $3.4 million from the private placement
• Potential additional $6.7 million in gross proceeds if all warrants are exercised for cash
• Insider participation, including CEO and CFO, at $1.47 per share and warrant
• Financing supports August 25, 2026 launch of direct-to-consumer skin renewal product

Negative

• Issuance of 2,293,608 shares plus associated warrants may create substantial dilution for existing shareholders
• Exercise of series E and F warrants depends on future stockholder approval
• Company notes there is no assurance that any warrants will be exercised for cash

News Explained

At June 30, cash equaled 164 days of Q2 operating cash use; the gross financing adds 126.4 days, while ownership dilution remains possible.

Dermata Therapeutics has entered definitive agreements, but the placement has not yet closed; the agreed shares, if issued, increase the share count and reduce existing holders’ percentage ownership absent offsetting changes, and each warrant series can add shares later.

The pre-funded-warrant alternative is a near-full-price instrument with a nominal exercise price that converts into shares when exercised, and it is offered here in lieu of common stock.

The extra warrant proceeds are conditional rather than committed: exercise starts only after effective stockholder approval, and the company gives no assurance that the warrants will be exercised or generate cash.

On the same second-quarter operating-cash-use basis, the $3.4 million gross offering equals 126.4 days, compared with 164 days for cash and equivalents at June 30, 2026.

The release makes closing, expected on or about August 18, 2026, subject to customary conditions, ties warrant exercise to effective stockholder approval, and says the company agreed to file a resale registration statement.

Sources and calculations

• Dermata Therapeutics private placement announcement (2026-08-17)
• Dilution definition (2026-07-17)
• Pre-funded warrant definition (2026-07-17)
• Dermata second-quarter 2026 fundamentals (2026Q2)

• Offering gross vs quarterly operating cash outflow, in days of cash use $3,400,000 / ($2,421,528 / 90) = [object Object]
• Cash and equivalents vs quarterly operating cash outflow, in days of cash use $4,412,764 / ($2,421,528 / 90) = [object Object]

Market Context

Dermata's active S-3 shelf, effective through November 21, 2028, placed this financing within an exi...

Analysis

Dermata's active S-3 shelf, effective through November 21, 2028, placed this financing within an existing capital-raising framework. The platform also recorded insider net selling, while warrant exercise remained unassured.

Key Figures

Upfront gross proceeds: $3.4 million Potential additional proceeds: approximately $6.7 million Shares offered: 2,293,608 shares +5 more

8 metrics

Upfront gross proceeds $3.4 million Private placement

Potential additional proceeds approximately $6.7 million If Series E and Series F warrants are fully exercised for cash

Shares offered 2,293,608 shares Common stock or pre-funded warrants

Purchase price $1.46 per share Common stock or pre-funded warrant with accompanying warrants

Series E warrant term five years From the effective date of stockholder approval

Series F warrant term twenty-four months From the effective date of stockholder approval

Expected closing August 18, 2026 Subject to customary closing conditions

Insider purchase price $1.47 per share Company insiders participating under Nasdaq rules

Previous Private placement Reports

5 past events · Latest: Dec 29 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 29	Private placement	Positive	+22.6%	Placement closing delivered upfront proceeds and additional warrant funding potential.
Dec 24	Private placement	Positive	+16.2%	Offering announcement disclosed upfront proceeds and additional warrant exercise potential.
Jan 23	Private placement	Positive	-1.7%	Offering closing provided financing for operations, development, acquisitions, and working capital.
Jan 22	Private placement	Positive	-16.5%	Offering announcement detailed proceeds, warrants, insider participation, and planned corporate uses.
Sep 17	Private placement	Positive	+9.2%	Placement closing raised proceeds for corporate purposes, research, trials, and acquisitions.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Private-placement announcements produced mixed 24-hour reactions, with both positive and negative moves in the tag-specific history.

Key Terms

private placement, pre-funded warrant, regulation d, resale registration statement

4 terms

private placement financial

"entered into definitive agreements for the issuance and sale"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

pre-funded warrant financial

"or pre-funded warrants in lieu thereof"

A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.

regulation d regulatory

"and/or Regulation D promulgated thereunder"

Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.

resale registration statement regulatory

"agreed to file a resale registration statement"

A resale registration statement is a document filed with regulators that allows existing shareholders to sell their shares to the public. It provides the necessary legal approval and information for these shares to be resold on the market, helping to increase the availability of shares for trading. For investors, it signals that shares held by current owners can be offered for sale, potentially affecting share prices and market liquidity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

$3.4 million upfront with up to approximately $6.7 million of potential additional gross proceeds upon the exercise in full of warrants

SAN DIEGO, CA / ACCESS Newswire / August 17, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,293,608 shares of common stock (or pre-funded warrants in lieu thereof), series E warrants to purchase up to 2,293,608 shares of common stock and short-term series F warrants to purchase up to 2,293,608 shares of common stock at a purchase price of $1.46 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under the rules of the Nasdaq Stock Market. The series E warrants and the series F warrants will have an exercise price of $1.46 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants. The series E warrants will expire five years from the effective date of stockholder approval and the series F warrants will expire twenty-four months from the effective date of stockholder approval. The closing of the offering is expected to occur on or about August 18, 2026, subject to the satisfaction of customary closing conditions.

Company insiders, including the Company's Chief Executive Officer, Chief Financial Officer and a certain member of the Company's management team, are participating in the offering. The purchase price per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants for these Company insiders is $1.47, in accordance with Nasdaq rules. The exercise price of the warrants purchased by the Company's insiders is $1.47.

The gross proceeds from the offering are expected to be approximately $3.4 million, prior to deducting offering expenses payable by the Company. The potential additional gross proceeds to the Company from the series E warrants and the short-term series F warrants, if fully exercised on a cash basis, will be approximately $6.7 million. No assurance can be given that any of the series warrants will be exercised, or that the Company will receive cash proceeds from the exercise of the series warrants. The Company intends to use the net proceeds from the offering for general corporate purposes which includes, without limitation, consumer research studies, pre-launch and launch activities for the Company's new direct-to-consumer product, investing in or acquiring companies that are synergistic with or complementary to the Company's technologies, licensing activities related to the Company's current and future product candidates, and to the development of emerging technologies, investing in or acquiring companies that are developing emerging technologies, licensing activities, or the acquisition of other businesses and working capital.

The securities described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the shares, warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement with investors, the Company has agreed to file a resale registration statement covering the securities described above.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Dermata Therapeutics
Dermata Therapeutics is a scientific leader in dermatologic solutions that recently announced a strategic pivot from pharmaceutical development to begin focusing on the development and commercialization of direct-to-consumer skincare solutions. The Company is currently developing a first-of-its-kind skin renewal treatment which incorporates Dermata's Bioneedle™. The Company expects to launch its first product on August 25, 2026, with additional innovations planned to follow. Dermata is headquartered in San Diego, California. For more information, or to join our mailing list, please visit http://www.dermatarx.com/.

Forward-looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other factors including, but are not limited to, statements related to: the completion of the offering; the satisfaction of customary closing conditions related to the offering; the intended use of proceeds therefrom; the receipt of stockholder approval; and the potential exercise of the series warrants and potential proceeds therefrom. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to, market and other conditions. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval, and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

Investors:
Cliff Mastricola
Investor Relations
cmastricola@dermatarx.com

SOURCE: Dermata Therapeutics

View the original press release on ACCESS Newswire

FAQ

What did Dermata Therapeutics (NASDAQ: DRMA) announce in its August 17, 2026 private placement?

Dermata Therapeutics announced a private placement to raise about $3.4 million upfront, with potential additional $6.7 million from warrant exercises. According to Dermata Therapeutics, the deal includes 2,293,608 shares (or pre-funded warrants) and series E and F warrants priced at-the-market.

How many shares and warrants are included in Dermata Therapeutics’ (DRMA) $3.4 million private placement?

The transaction covers 2,293,608 shares of common stock (or pre-funded warrants) and series E and series F warrants for up to 2,293,608 shares each. According to Dermata Therapeutics, all securities are priced at $1.46 per share and accompanying warrants for non-insider investors.

What are the exercise prices and terms of the Dermata Therapeutics (DRMA) series E and F warrants?

Both series E and F warrants have an exercise price of $1.46 per share for non-insiders, becoming exercisable upon stockholder approval. According to Dermata Therapeutics, series E warrants expire five years after approval, while series F warrants expire twenty-four months after approval.

How are Dermata Therapeutics (DRMA) insiders participating in the August 2026 private placement?

Company insiders, including the CEO, CFO and a management member, are participating at a $1.47 purchase and warrant exercise price. According to Dermata Therapeutics, this insider pricing complies with Nasdaq rules and reflects slightly higher terms than non-insider investors in the offering.

What will Dermata Therapeutics use the DRMA private placement proceeds for?

Net proceeds are earmarked for general corporate purposes, including consumer research, pre-launch and launch activities for a direct-to-consumer skincare product, licensing and potential acquisitions. According to Dermata Therapeutics, funds will also support development of emerging technologies and provide additional working capital flexibility.

When is Dermata Therapeutics (DRMA) planning to launch its new direct-to-consumer product?

Dermata Therapeutics expects to launch its first direct-to-consumer skin renewal treatment on August 25, 2026. According to Dermata Therapeutics, the product incorporates its Bioneedle technology and the private placement proceeds will help fund pre-launch and launch-related commercialization activities.

Are the Dermata Therapeutics (DRMA) private placement securities registered and freely tradable?

The securities are initially unregistered, offered under Section 4(a)(2) and/or Regulation D exemptions from the Securities Act. According to Dermata Therapeutics, the company agreed to file a resale registration statement to cover these securities for potential future public resale by investors.